Vimta Labs Limited — Investor Meet, 05-05-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Vimta Labs reported Q4 revenue up 31.4% YoY to INR96.1 Cr and FY25 revenue growth of 19.1% to INR348.2 Cr, led by pharmaceutical services. EBITDA margin remained steady at ~36%, PAT margin at 19%. Net debt-free with INR32.9 Cr cash. FY26 capex planned at ~INR90 Cr mainly for equipment, supporting expansion in biologics CDMO and life sciences services. Exports contribute 36%, mostly from the U.S. Despite pricing pressures, management expects healthy demand and aims for a Q4 FY26 revenue run rate of INR125 Cr. Focus remains on pharma and food with high repeat clientele and steady margin outlook.